UPDATE: Aegis Capital Initiates Amarin Corporation with Buy, $25 PT; Risk-Mitigated Opportunity
Aegis Capital said on Monday that it initiated coverage on Amarin Corporation (NASDAQ: AMRN) with a Buy rating and a price target of $25.
Aegis Capital said, "In our view, Amarin constitutes one of the most risk-mitigated opportunities in the biotechnology sector, as the firm's lead product candidate has already successfully demonstrated safety and efficacy in two randomized, placebo-controlled Phase 3 clinical trials. These studies were conducted under Special Protocol Assessments (SPAs) from the U.S. FDA."
Amarin Corporation closed at $15.12 on Friday.
© 2014 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.